Emergent BioSolutions (EBS) announced that brincidofovir will be included in a clinical trial conducted and sponsored by Panther, under the leadership of the Africa Centres for Disease Control and Prevention, as part of the ‘MpOx Study in Africa’. The study will evaluate the safety and efficacy of brincidofovir in treating mpox virus in a randomized double-blind placebo-controlled trial.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EBS:
- Emergent BioSolutions Reports Strong Q3 2024 Results
- Emergent BioSolutions narrows FY24 revenue view to $1.065B-$1.125B
- Emergent BioSolutions reports Q3 adjusted EPS $1.37 vs. ($1.09) last year
- Emergent BioSolutions appoints Lowry as Chief Medical Officer
- EBS Earnings Report this Week: Is It a Buy, Ahead of Earnings?